Anna Rachelle Mislang

Author

Also Known As

A. Mislang, A.R. Mislang, A.R.A. Mislang, Anna Mislang, Anna R A Mislang, Anna Rachelle Austria Mislang, Anna Rachelle Mislang

Publications

549

Citations

H-Index

Concepts

All Affiliations

Centre for Cancer Biology Flinders University Cancer Council Queensland Flinders Medical Centre Blacktown & Mount Druitt Hospital

About

Anna Rachelle Mislang is an author at Centre for Cancer Biology specializing in oncology, cancer therapeutics, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	59
2	Immunology	3	3	48
3	Pathology	2	2	31
4	Health Sciences	1	1	11
5	Adaptive Radiotherapy	1	1	11

Anna Rachelle Mislang

Publications

282

Citations

H-Index

Page 1

	Year	Citations
Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group Nicolò Matteo Luca Battisti, Anna Rachelle Mislang, Lisa Cooper, Journal of Geriatric Oncology	2020	78
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors Sophia Frentzas, Anna Rachelle Mislang, Charlotte Lemech, Journal for ImmunoTherapy of Cancer	2024	51
Screening for Frailty in Older Patients With Early-Stage Solid Tumors: A Prospective Longitudinal Evaluation of Three Different Geriatric Tools Laura Biganzoli, Anna Rachelle Mislang, Samantha Di Donato, The Journals of Gerontology Series A	2017	30
Geriatric assessment for older people with cancer: policy recommendations Shabbir M.H. Alibhai, Nicolò Matteo Luca Battisti, Ravindran Kanesvaran, Global Health Research and Policy	2023	25
Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers Yulong Zheng, Anna Rachelle Mislang, Jermaine Coward, Cancer Immunology Immunotherapy Gastrointestinal OncologyMedicineImmunologyPathologyImmune Checkpoint Inhibitor	2022	18
Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study. Hui Gan, Jermaine Coward, Anna Rachelle Mislang, Journal of Clinical Oncology ImmunologyImmunoeditingPreliminary Ak117 SafetyImmunotherapeuticsImmunotherapy	2021	17
NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma Hao‐Wen Sim, Elizabeth H Barnes, Sonia Yip, Neuro-Oncology Advances	2023	17
Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study. Jermaine Coward, Anna Rachelle Mislang, Sophia Frentzas, Journal of Clinical Oncology Tetrameric Bispecific AntibodySerum VegfMedicineImmunologyTumor Immunity	2021	13
EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer Laura Biganzoli, Saverio Cinieri, Rossana Berardi, Breast Cancer Research	2020	12
Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small-cell lung cancer Nimit Singhal, Anna Rachelle Mislang, Christos S. Karapetis, Anti-Cancer Drugs Adaptive RadiotherapyHealth SciencesRadiation TherapyConcomitant RadiotherapyMv Photons	2015	11

Page 1